Showing results (91-100 of 676) with videos related to
Sort By:
Pageof 68
CNS Drugs|September 28, 2005
Evaluation of HMG-CoA reductase inhibitors for multiple sclerosis: opportunities and obstaclesOliver Neuhaus, Olaf Stüve, Scott S Zamvil, et al.Handbook of Clinical Neurology|February 11, 2014
Immune regulation of multiple sclerosisHans-Peter Hartung, Orhan Aktas, Til Menge, et al.Neurology|April 27, 2005
Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationaleGeorge P A Rice, Hans-Peter Hartung, Peter A CalabresiNeurology|June 13, 2014
Alemtuzumab: the advantages and challenges of a novel therapy in MSTil Menge, Olaf Stüve, Bernd C Kieseier, et al.Neurology|December 25, 2003
Cyclo-oxygenases and prostaglandins in acute inflammatory demyelination of the peripheral nerveWei Hu, Emily Mathey, Hans-Peter Hartung, et al.Pharmacological Research|September 1, 2009
The future of multiple sclerosis therapyBernd C Kieseier, Heinz Wiendl, Hans-Peter Hartung, et al.Journal of the Peripheral Nervous System : JPNS|October 14, 2005
Tumor necrosis factor-alpha-converting enzyme is expressed in the inflamed peripheral nervous systemMartin Kurz, Heidrun Pischel, Hans-Peter Hartung, et al.Handbook of Clinical Neurology|August 13, 2013
Treatment of chronic inflammatory demyelinating polyradiculoneuropathyHelmar C Lehmann, Richard A C Hughes, Hans-Peter HartungJournal of the Neurological Sciences|June 14, 2005
Putative mechanisms of action of statins in multiple sclerosis--comparison to interferon-beta and glatiramer acetateOliver Neuhaus, Olaf Stüve, Juan J Archelos, et al.Current Opinion in Neurology|May 6, 2025
Immunology of multiple sclerosis: an updatePatricia Kirschner, Marc Pawlitzki, Hans-Peter Hartung, et al.Pageof 68